Legal Representation
Attorney
April L. Besl
USPTO Deadlines
Next Deadline
28 days remaining
Final Refusal E-Mailed - 3-Month Extension Granted (XELG on 2025-11-04)
Due Date
February 07, 2026
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 4, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Nov 4, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Sep 26, 2025 | GNS1 | O | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | Loading... |
| Sep 26, 2025 | GNSF | O | SUBSEQUENT FINAL EMAILED | Loading... |
| Sep 26, 2025 | CFRC | R | SUBSEQUENT FINAL REFUSAL WRITTEN | Loading... |
| Aug 7, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Aug 7, 2025 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Aug 7, 2025 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jun 18, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 18, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 18, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 13, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Feb 13, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Dec 19, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 19, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 19, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 13, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 10, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 31, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
active pharmaceutical ingredients, namely, isotopes and radioisotopes for medical, therapeutic and diagnostic use; active pharmaceutical ingredients, namely lutetium-177, for medical, therapeutic and diagnostic use; active pharmaceutical ingredients, namely non-carrier added lutetium 177; active pharmaceutical ingredients, namely, a radioisotope for the diagnosis and treatment of oncological diseases and disorders; active pharmaceutical ingredients, namely, a radioisotope for the purpose of increasing the effectiveness of pharmaceutical preparations in the treatment of oncological diseases
Classification
International Classes
005